Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Penpulimab - Akeso Biopharma/Chia Tai Tianqing Pharmaceutical Group

Next Previous
X
Search
Drug Profile

Penpulimab - Akeso Biopharma/Chia Tai Tianqing Pharmaceutical Group

Alternative Names: AK 105 - Akeso Biopharma/Chia Tai Tianqing Pharmaceutical Group; Anniko

Latest Information Update: 27 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Developer Akeso Biopharma; Beijing Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group; Fudan University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nasopharyngeal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hodgkin's disease; Nasopharyngeal cancer; Non-small cell lung cancer
  • Preregistration Liver cancer
  • Phase II Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Neuroendocrine tumours; Pancreatic cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Urogenital cancer
  • Phase I/II Mesothelioma; Oesophageal cancer; Thymoma; Uterine cancer

Most Recent Events

  • 22 Nov 2024 Preregistration for Liver cancer (Combination therapy, First-line therapy, Late-stage disease) in China (IV) (9430769
  • 22 Nov 2024 Preregistration for Nasopharyngeal cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in China (IV) before November 20204
  • 22 Nov 2024 Preregistration for Nasopharyngeal cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV) before November 20204

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top